Early hormone therapy linked to lower heart attack and stroke risk in women
A 20-year study of nearly 2800 women found that starting hormone replacement therapy during perimenopause or early menopause was associated with a lower risk of heart attacks and stroke. The researchers caution that the findings do not support using HRT solely to prevent cardiovascular disease, and more research is needed on optimal timing. The study addresses earlier controversies by focusing on women in their 40s and 50s rather than older participants.
The research tracked 2,737 women over two decades, recording 224 cardiovascular events among the group. Only 755 participants used some form of hormone therapy during the study window. Women who began treatment within a decade of their first vasomotor symptoms showed a 27 percent lower likelihood of experiencing heart attacks or stroke compared with non-users, while those who started later showed no clear benefit.
This work directly addresses a long-standing controversy in women's health. The 2002 trial that linked HRT to increased cardiovascular risks studied participants who were typically around age 60, well past the typical menopausal transition. By focusing on women in their 40s and 50s, this study offers a more relevant picture of how treatment timing affects outcomes, though researchers stress the mechanisms remain poorly understood.
This research could reshape how clinicians and patients approach menopause treatment decisions, potentially easing fears that have persisted since the early 2000s. Women experiencing perimenopause may feel more confident discussing HRT options with their doctors, though the researchers explicitly caution against using it solely for heart protection. The findings may also prompt further investigation into racial differences in menopause experiences, since Black participants appeared to benefit most. Ultimately, this could influence clinical guidelines, but broader societal impact depends on whether future studies confirm these timing-related findings.